Open channel block of Kv1.5 currents by citalopram

Hyang Mi LEE¹, Sang June HAHN², Bok Hee CHOI¹, *

¹Department of Pharmacology, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju, Jeonbuk 561–180, Republic of Korea; ²Department of Physiology, College of Medicine, the Catholic University of Korea, Seoul 137–701, Republic of Korea

Aim: To examine whether selective serotonin reuptake inhibitor citalopram interacts with Kv1.5, one of the cardiovascular-specific Kv channel isoforms.

Methods: The interaction between citalopram and Kv1.5 expressed in Chinese hamster ovary cells was studied using the whole-cell patch-clamp technique.

Results: Citalopram reduced Kv1.5 whole-cell currents in a reversible concentration-dependent manner, with an IC₅₀ value and a Hill coefficient of 2.8±1.1 µmol/L and 0.8±0.3, respectively. Citalopram-induced inhibition of Kv1.5 is associated with time-dependent development of block without modifying the kinetics of current activation. The inhibition increased steeply between -30 and 0 mV, which corresponded with the voltage range for channel opening. In the voltage range positive to 0 mV, inhibition displayed an additional voltage dependence, consistent with an electrical distance δ of 0.19. Citalopram slowed the deactivation time course, resulting in a tail crossover phenomenon when the tail currents, recorded in the presence and absence of citalopram, were superimposed. Inhibition of Kv1.5 by citalopram was use-dependent.

Conclusion: The present results suggest that citalopram acts on Kv1.5 currents as an open-channel blocker, and much caution about arrhythmogenic risk is required when using citalopram in the treatment with depressed patients.

Keywords: citalopram; serotonin reuptake inhibitors; Kv1.5; Shaker-type K⁺ channels; open channel block

Introduction
Selective serotonin reuptake inhibitor (SSRI) is thought to be safer than tricyclic antidepressant (TCA) in the risk of cardiovascular causes, because TCA is known to induce QT prolongation of the electrocardiogram and the associated arrhythmogenic risk in vivo[1–4]. Citalopram is a SSRI and the drug exerts its antidepressant activity by inhibiting the reuptake of 5-hydroxytryptamine (5-HT, serotonin) in the central nervous system, without critical effects on other neurotransmitter reuptake systems[5–8]. Therefore, citalopram may be an attractive drug for treatment of patients suffering from the cardiovascular adverse effects of TCA. However, accumulating evidence indicates that citalopram may lead to cardiovascular risk within the clinical range[9–11]. Furthermore, citalopram inhibits voltage-gated Ca²⁺ channels, Na⁺ channels and K⁺ channels in ventricular myocytes or cardiovascular smooth muscle cells[12–16]. Pharmacological blockade of voltage-gated K⁺ channels (Kv channels) in cardiac muscle has been associated with adverse cardiac arrhythmias, suggesting that citalopram may interact with cardiac Kv channels. However, the effects of citalopram on cardiac Kv channels remain to be elucidated.

Kv1.5 is one of the cardiovascular-specific Kv channel isoforms. Kv1.5 channels play an important role in determining the length of cardiac action potentials and, therefore, have been the targets of antiarrhythmic drugs[17, 18]. Because of its rapid activation and little inactivation, Kv1.5 can contribute to repolarization of atrial action potentials. Dysfunction of Kv1.5 results in a prolongation of cardiac action potentials, which eventually leads to cardiac arrhythmias with serious morbidity[19–21].

In this study, we investigated whether citalopram interacts with Kv1.5 cloned from the rat brain, and determined the mechanisms of actions of citalopram on the Kv1.5.

Materials and methods
Cell culture and transfection
Chinese hamster ovary (CHO) cells expressing Kv1.5 channels derived from rat brain were used for electrophysiological recordings[21]. Kv1.5 cDNA[22] was transferred into the plasmid expression vector pCR3.1 (Invitrogen Corporation, San Diego, CA, USA). CHO cells were transfected with Kv1.5 cDNA...
using FuGENE™6 reagent (Boehringer Mannheim, Indianapolis, IN, USA). The transfected cells were cultured in Iscove’s modified Dulbecco’s medium (Invitrogen Corporation) supplemented with 10% fetal bovine serum, 2 mmol/L glutamine, 0.1 mmol/L hypoxanthine, 0.01 mmol/L thymidine, and 300 µg/ml G418 (AG Scientific, San Diego, CA, USA) in 95% humidified air-5% CO₂ at 37 °C. The cultures were passaged every 4–5 d with a brief trypsin-EDTA treatment followed by seeding onto glass coverslips (diameter: 12 mm, Fisher Scientific, Pittsburgh, PA, USA) in a Petri dish. After 12–24 h, the cell-attached coverslips were used for electrophysiological recordings.

Electrophysiology
Kv1.5 currents were recorded from CHO cells, with a whole-cell patch-clamp technique[23] at room temperature (22–23 °C). The micropipettes fabricated from glass capillary tubing (PG10165-4; World Precision Instruments, Sarasota, FL, USA) with a double-stage vertical puller (PC-10; Narishige, Tokyo) had a tip resistance of 2–3 MΩ when filled with the pipette solution. Whole-cell currents were amplified with MultiClamp 700B amplifier (Molecular Devices, Sunnyvale, CA, USA), digitized with Digidata 1440A (Molecular Devices) at 5 kHz and low-pass filtered with four-pole Bessel filter at 2 kHz. Capacitive currents were canceled and series resistance was compensated at 80% with the amplifier, while leak subtraction was not used. The generation of voltage commands and acquisition of data were controlled with pClamp 10.1 software (Molecular Devices) running on an IBM-compatible Pentium computer. Recording chamber (RC-13, Warner Instrument Corporation, Hamden, CT, USA) was continuously perfused with bath solution (see below for composition) at a rate of 1 mL/min.

Solutions and drugs
The intracellular pipette solution for whole-cell recordings contained 140 mmol/L KCl, 1 mmol/L CaCl₂, 1 mmol/L MgCl₂, 10 mmol/L HEPES, and 10 mmol/L EGTA, and was adjusted to pH 7.3 with KOH. The bath solution for whole-cell recordings contained 140 mmol/L NaCl, 5 mmol/L KCl, 1.3 mmol/L CaCl₂, 1 mmol/L MgCl₂, 20 mmol/L HEPES and 10 mmol/L glucose, and was adjusted to pH 7.3 with NaOH. Citalopram (Sigma Chemical Co, Saint Louis, MO, USA) was dissolved in ethanol at 30 mmol/L and further diluted into the bath solution. Final concentration of ethanol in the bath solution, which was less than 0.1%, had no effect on Kv1.5 currents.

Data analysis
Data were analyzed with Origin 7.0 (OriginLab Corp, Northampton, MA, USA) and Clampfit 10.1 software (Molecular Devices). IC₅₀ and Hill coefficient (n) were obtained from fitting concentration dependence data to the following equation:

\[ I(\%) = \frac{100 - I_{\text{drug}}}{I_{\text{control}}} \times 100 \]

in which I (%) is the percent inhibition of current (I(%)=[1−I_{\text{drug}}/I_{\text{control}}]×100) at test potential and [D] represents various drug concentrations. The steady-state activation curves were fitted with the Boltzmann equation:

\[ y = \frac{1}{1 + \exp\left(\frac{(V - V_{1/2})}{k}\right)} \]

where k represents the slope factor, V the test potential, and V₁/₂ the potential at which the conductance was half-maximal. An activation time constant was calculated by fitting the latter 50% of activation (ie, rise from 50% to 100% of peak amplitude) with a single exponential function. The drug-induced time constant and deactivation time constant were determined by fitting with the sum of the exponentials:

\[ y = B + A_1 \exp\left(-t/\tau_1\right) + A_2 \exp\left(-t/\tau_2\right) + \ldots + A_n \exp\left(-t/\tau_n\right) \]

in which \( \tau_1, \tau_2, \ldots, \tau_n \) are the time constants; \( A_1, A_2, \ldots, A_n \) are the amplitudes of each component of the exponential; and B is the baseline value.

To investigate the voltage dependence of Kv1.5 inhibition by the drug, the relative current was plotted as a function of the membrane potential. The resultant percent inhibition data between 0 and +50 mV were fitted with a Woodhull equation[24]:

\[ I(\%) = \frac{K_0[D]}{K_0[D] + \exp\left(-2\delta F V/RT\right)} \]

where \( K_0 \) represents the apparent affinity at 0 mV, \( \delta \) the fractional electrical distance, \( F \) Faraday’s constant, \( R \) the gas constant, and \( T \) the absolute temperature. A value of 25.4 mV was used for \( RT/F \) at 22 °C in the present study. Equation 6 can be modified to get a linear transformation as follows:

\[ \ln\left(I_{\text{control}} - I_{\text{drug}}\right) = \ln\left([D]/[K_0(0)]\right) + \delta z F V/RT \]

Results
Concentration-dependent inhibition of Kv1.5 by citalopram
As shown in Figure 1A, Kv1.5 currents were activated under control conditions with a fast rising to a peak and then slowly inactivated, as reported previously[21]. The dominant time constant of activation under control conditions was 1.5±0.2 ms \((n=4)\) with a 250-ms depolarizing pulse from -80 to +50 mV. In the presence of 3 µM citalopram, the time constant of activation was 1.46±0.18 ms \((n=4)\), which indicates that the activation kinetics were not significantly modified by citalopram. When exposed to different concentrations of citalopram (0.3, 1, 3, 10, 30 µmol/L), the Kv1.5 currents were inhibited in a concentration-dependent manner. Figure 1B shows the concentration dependence of Kv1.5 current inhibition by citalopram. Inhibition of the current was measured at the end of a 250-ms pulse of +50 mV. A nonlinear least-squares fit of the Hill equation to the individual data points yielded an IC₅₀ value and a Hill coefficient of 2.8±1.1 µmol/L and 0.8±0.3 \((n=6)\), respectively. As shown in Figure 1C, when switched to solutions containing citalopram, inhibition of Kv1.5 reached a steady state within 2 min, resulting in 52.1±6.5% control value measured at the end of a depolarizing pulse of +50 mV \((n=4)\). The wash-out by perfusion of drug-free solution was also reached within 2 min, and currents recovered to 81.4±7.5% of control value.
(n=4), indicating that effects of citalopram were largely reversible upon washout.

Voltage-dependent inhibition of Kv1.5 by citalopram
Figure 2 shows the effect of 3 µmol/L citalopram on current-voltage (I–V) relations. Under control conditions, the Kv1.5 current activated at pulses greater than -30 mV, and the steady-state I–V relationship showed a sigmoidal shape at potentials between -30 and 0 mV (Figure 2A and 2C). The inhibition of Kv1.5 currents by 3 µmol/L citalopram was observed in the whole voltage range over which Kv1.5 was activated (Figure 2B and 2C). By plotting percent inhibition (see Materials and methods) versus potential, a high degree of inhibition with a strong voltage dependence was observed between -30 and 0 mV, which involved the voltage range of channel opening (Figure 2D). Between 0 and +50 mV, despite Kv1.5 being fully activated at this voltage range, inhibition continued to increase with a shallow voltage dependence: 41.3±2.7% inhibition at 0 mV, and 47.0±1.8% at +50 mV (n=4, P<0.05). Given the assumption that citalopram interacts intracellularly with Kv1.5, we investigated this effect by a linear curve fitting of the data at potentials positive to 0 mV, using a linear transformation of Woodhull equation (see Materials and methods). The solid lines in Figure 2D represents a fitted curve which yielded δ=0.19±0.02 (n=4).

Time-dependent inhibition of Kv1.5 by citalopram
Figure 3A shows the effect of citalopram on the time course of channel current during the 250-ms depolarizing pulse at +50 mV. With a single exponential fitting to the traces of current decay at each concentration of citalopram, time constants were obtained. To avoid contamination by the time constant of the intrinsic slow and partial inactivation current of Kv1.5 under control conditions, a time constant value obtained at low concentrations (0.3 and 1 µmol/L) of citalopram was omitted. Figure 3B shows a summary of the time constants at various concentrations of citalopram. The values of time constant decreased as the concentration of citalopram increased, suggesting that the concentration-dependent citalopram-induced inhibition of Kv1.5 is associated with time-dependent development of block.

To further investigate the time-dependent inhibition of Kv1.5 by citalopram, the effect of citalopram on the Kv1.5 current deactivation kinetics was studied. Figures 4A shows the representative superimposed tail currents recorded with a 250-ms repolarizing pulse at -40 mV after a 250-ms depolarizing pulse of +50 mV from a holding potential of -80 mV, under control conditions and in the presence of 3 µmol/L citalopram. Under control conditions, the tail current declined quickly with a time constant of 26.3±1.9 ms (n=4) and was nearly completely deactivated during a 250-ms repolarizing pulse of -40 mV. In the presence of 3 µmol/L citalopram, the initial peak amplitude of the tail current was reduced and the subsequent decline of the current was slower (53.4±2.2 ms, n=4), which resulted in the tail crossover phenomenon. Figure 4B shows a summary of the time constants obtained at repolarizing pulses of -40 mV. Citalopram significantly increased the deactivation time constants of Kv1.5 at repolarizing pulses of -40 mV (n=4, P<0.05).

Use-dependent inhibition of Kv1.5 by citalopram
Figure 5A shows the original current traces in the absence and presence of 3 µmol/L citalopram obtained from applying

Figure 1. Concentration dependence of citalopram-induced inhibition of Kv1.5 currents. (A) Superimposed current traces were produced by applying 250-ms depolarizing pulses from a holding potential of -80 to +50 mV followed by a 250-ms repolarizing pulse to -40 mV every 10 s in the absence and presence of 0.3, 1, 3, 10, and 30 µmol/L citalopram, as indicated. The dotted line represents zero current. (B) Concentration-dependent curve of inhibition by citalopram. Current amplitudes of Kv1.5 measured at the end of the depolarizing pulses were used as an index of steady-state inhibition, and percentage inhibition was plotted against various concentrations of citalopram. The solid line is fitted to the data points by the Hill equation. (C) Time course for inhibition in the presence of 3 µmol/L citalopram. The current amplitudes were measured at the end of a 250-ms depolarizing pulses from a holding potential of -80 to +40 mV every 10 s in the presence of 3 µmol/L citalopram and normalized to the first current amplitude and the normalized data were plotted as a function of time. Data are expressed as mean±SEM.
20 repetitive 125-ms depolarizing pulses of +50 mV from a holding potential of -80 mV at 1 and 2 Hz. After the 2-min exposure to 3 µmol/L citalopram with a holding potential of -80 mV, this repetitive pulse protocol was applied. Figure 5B shows the normalized current amplitudes at two different frequencies, 1 and 2 Hz in the absence and presence of 3 µmol/L citalopram during application of the pulse trains. Under control conditions, the peak amplitude of the Kv1.5 current slightly decreased by 6.8±1.5% (n=4) at 1 Hz and by 12.1±2.1% (n=4) at 2 Hz in a weak frequency-dependent manner. In the presence of 3 µmol/L citalopram, the peak amplitude of Kv1.5 progressively decreased by 30.6±3.1%
Discussion

The present study shows the effects of citalopram on the Kv1.5 expressed in CHO cells, using the patch-clamp technique.

The characteristics of the citalopram-induced inhibition of Kv1.5 were as follows. 1) The inhibition of Kv1.5 by citalopram is associated with time-dependent development of block with no effect on the activation kinetics of Kv1.5, suggesting that citalopram does not bind to the closed or resting state of Kv1.5 and the drug preferentially interacts with the open state of Kv1.5. 2) The inhibition of Kv1.5 induced by citalopram was highly voltage-dependent and increased steeply in the voltage range of channel activation. The voltage-dependent inhibition of Kv1.5 by citalopram implies that the inhibition of Kv1.5 by citalopram occurs preferentially after the channels are open[21, 25, 26]. 3) Citalopram slowed the deactivation time course, resulting in a tail crossover phenomenon. This can be explained if the dissociation rate of citalopram is lower than the transition rate between the open and the closed (or resting) state under control conditions. This tail crossover phenomenon suggests an interaction between citalopram and the open state of Kv1.5 as previously reported[21, 26, 27]. 4) The actions of citalopram in inhibiting Kv1.5 were use-dependent, with effects enhanced at higher rates of channel activation. One of the features of open channel blockers is a use-dependent inhibition because the blockers would have a higher chance to bind to channel pores as the channels open more frequently[21, 25, 26, 28]. This is consistent with the actions of citalopram on the open state of Kv1.5. The above summarized results suggest that citalopram acts on the Kv1.5 as an open channel blocker.

An additional shallow degree of inhibition was detected in...
the voltage range positive to 0 mV despite Kv1.5 being fully activated at this voltage range. This weak but significant voltage-dependent inhibition was considered the consequence of the effects of the transmembrane electrical field on the interaction between citalopram and Kv1.5. If a positively charged drug moves into the transmembrane electric field from the inside, then inhibition should increase upon depolarization due to electrostatic repulsion between a positively charged citalopram and membrane depolarizing potential. This will occur in the voltage range where channels are in the open state and should also occur over the voltage range where channels are fully activated. At an intracellular pH of 7.3, citalopram is mainly positively charged because the drug is a weak base with a $pK_a=9.59[^{29}]$. Given the assumption that citalopram interacts intracellularly with Kv1.5, the positively charged drug appears to move into the transmembrane electric field from the inside. Inhibition should then increase at more depolarizing potentials because of electrostatic repulsion between the charge and the potentials, over the voltage range where the channels are fully activated. The $\delta$ value of 0.19 for the shallow voltage dependence indicates that the positively charged citalopram senses 19% of the applied transmembrane electrical field as referenced from the intracellular side. This value is similar to the $\delta$ values of 0.16 – 0.19 obtained in previous experiments with open channel blockers of Kv1.5[^30–32].

Although citalopram is thought to be safer than TCA in the risk of cardiovascular causes, accumulating evidence indicates that citalopram may lead to cardiovascular risk within the clinical range[^9, 10, 33]. On the basis of pharmacokinetics of citalopram, the therapeutic plasma concentrations of citalopram is reported to be less than 1 $\mu$mol/L in human depressed patients[^34–37]. In the present study, the IC$_{50}$ value (2.9 $\mu$mol/L) of citalopram for blocking Kv1.5 is higher than therapeutic plasma concentrations. However, significant inhibitions of Kv1.5 currents at concentrations of 0.3 or 1 $\mu$mol/L were detected. Furthermore, the effects of citalopram on Kv1.5 were examined in a CHO cell line in the present study. The phospholipid composition of the cell may be different from human native cardiac myocytes and the differences of membrane composition may affect citalopram-induced Kv1.5 blockade. And also, drug concentrations in tissues may be higher than in plasma due to its high lipophilicity and affinity for adipose tissues. Therefore, it is possible that in the present study, the extent of the blocking effects of citalopram on Kv1.5 under physiological conditions may be underestimated. That is, the citalopram-induced block of Kv1.5 channel could be clinically relevant in the upper range of therapeutic plasma concentrations that are observed in treatment with citalopram for depressed patients. Finally, in cardiomyocytes, it is most likely that citalopram may lead to cardiac disorder through block of Kv1.5 channel resulting in a significant prolongation of the action potential or arrhythmia phenomenon in the native cardiac myocytes or animal heart.

In conclusion, the present study has described the effects of citalopram on the Kv1.5 channel expressed in Chinese hamster ovary cells. Detailed study of the interaction kinetics between citalopram and Kv1.5 suggests that citalopram is an open-channel blocker for Kv1.5 in a concentration-, voltage-, time-, and use-dependent manner. Thus, much caution about arrhythmmogenic risk is required when using citalopram in the treatment with depressed patients.

Acknowledgements

We thank Dr Leonard KACZMAREK (Yale University School of Medicine, USA) for the Kv1.5 cDNA.

Author contribution

Hyang Mi LEE designed research, performed research, analyzed data and wrote the paper. Sang June HAHN analyzed data and wrote the paper. Bok Hee CHOI designed research, performed research, analyzed data and wrote the paper.

References

1. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310: 221–4.
2. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997; 16: 374–90.
3. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–52.
4. Scherer D, von Lowenstern K, Zitron E, Scholz EP, Bloehs R, Kathofer S, et al. Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 73–83.
5. Rose SP, Spatz E. Treatment of depression in patients with heart disease. J Clin Psychiatry 1999; 60: 34–7.
6. Keller MB. Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials. J Clin Psychiatry 2000; 61: 896–908.
7. Parker NG, Brown CS. Citalopram in the treatment of depression. Ann Pharmacother 2000; 34: 761–71.
8. Spadone C. Efficacy of escitalopram and severity of depression: New data. Encephale 2009; 35: 577–85.
9. Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G. Arrhythmogenic risk is required when using citalopram in the treatment with depressed patients.
15 Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002; 512: 59–66.
16 Zahradnik I, Minarovic I, Zahradnikova A. Inhibition of the cardiac L-type calcium current by antidepressant drugs. J Pharmacol Exp Ther 2008; 324: 977–84.
17 Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990; 82: 2235–42.
18 Schumacher SM, McEwen DP, Zhang L, Arendt KL, Van Genderen KM, Martens JR. Antiarrhythmic drug-induced internalization of the atrial-specific K⁺ channel Kv1.5. Circ Res 2009; 104: 1390–8.
19 Wang Z, Ferrini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K⁺ current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73: 1061–76.
20 Li GR, Feng J, Yue L, Carrier M, Nattel S. Evidence for two components of delayed rectifier K⁺ current in human ventricular myocytes. Circ Res 1996; 78: 689–96.
21 Choi BH, Choi JS, Jeong SW, Hahn SJ, Yoon SH, Jo YH, et al. Direct block by bisindolylmaleimide of rat Kv1.5 expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 2000; 293: 634–40.
22 Swanson R, Marshall J, Smith JS, Williams JB, Boyle MB, Folander K, et al. Cloning and expression of cDNA and genomic clones encoding three delayed rectifier potassium channels in rat brain. Neuron 1990; 4: 929–39.
23 Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981; 391: 85–100.
24 Woodhull AM. Ionic blockage of sodium channels in nerve. J Gen Physiol 1973; 61: 687–708.
25 Delpo E, Valenzuela C, Gay P, Franqueza L, Nattel S, Tajmaro J. Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 1997; 35: 341–50.
26 Sung MJ, Hahn SJ, Choi BH. Effect of psoralen on the cloned Kv3.1 currents. Arch Pharm Res 2009; 32: 407–12.
27 Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhee DJ, Yoon SH, et al. Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone. Naunyn Schmiedebergs Arch Pharmacol 2007; 374: 305–9.
28 Wu J, Ding WG, Matsuura H, Tsuji K, Zang WJ, Horie M. Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel. Br J Pharmacol 2009; 156: 377–87.
29 Vasskog T, Berger U, Samuelsen PJ, Kallenborn R, Jensen E. Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromsø, Norway. J Chromatogr A 2006; 1115: 187–95.
30 Nattel S, Knott KM, Roberds SL, Tamkun MM. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol 1992; 41: 322–30.
31 Franqueza L, Valenzuela C, Delpo E, Longobardo M, Caballero R, Tamargo J. Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels. Br J Pharmacol 1998; 125: 969–78.
32 Valenzuela C, Delpo E, Franqueza L, Gay P, Perez O, Tamargo J, et al. Class III antiarrhythmic effects of zatebradine: time-, state-, use-, and voltage-dependent block of hKv1.5 Channels. Circulation 1996; 94: 562–70.
33 Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet 1996; 348: 339–40.
34 Fredricson Overo K. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 311–8.
35 Macek J, Ptáček P, Klíma J. Rapid determination of citalopram in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 755: 279–85.
36 Bjørkenstedt L, Flyckt L, Fredricson Overo K, Lingéarde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. Eur J Clin Pharmacol 1985; 28: 553–57.
37 Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547–52.